Contribution	contribution	O	O
of	of	O	O
sodium	sodium	B_chemicals	O
valproate	valproate	I_chemicals	O
to	to	O	O
the	the	O	O
syndrome	syndrome	O	S_disease
of	of	O	O
inappropriate	inappropriate	O	B_disease
secretion	secretion	O	I_disease
of	of	O	O
antidiuretic	antidiuretic	B_chemicals	B_disease
hormone	hormone	S_chemicals	I_disease
.	.	O	O

We	we	O	O
report	report	O	O
the	the	O	O
case	case	O	O
of	of	O	O
a	a	O	O
62-year-old	62-year-old	O	O
man	man	O	O
who	who	O	O
was	was	O	O
administered	administered	O	O
sodium	sodium	B_chemicals	O
valproate	valproate	I_chemicals	O
(	(	O	O
VPA	vpa	O	O
)	)	O	O
and	and	O	O
who	who	O	O
subsequently	subsequently	O	O
developed	developed	O	O
the	the	O	O
syndrome	syndrome	O	S_disease
of	of	O	O
inappropriate	inappropriate	O	B_disease
secretion	secretion	O	I_disease
of	of	O	O
antidiuretic	antidiuretic	B_chemicals	B_disease
hormone	hormone	S_chemicals	I_disease
(	(	O	O
SIADH	siadh	O	S_disease
)	)	O	O
.	.	O	O

He	he	O	O
had	had	O	O
been	been	O	O
taking	taking	O	O
VPA	vpa	O	O
for	for	O	O
treatment	treatment	O	O
of	of	O	O
idiopathic	idiopathic	O	O
generalized	generalized	O	B_disease
tonic-clonic	tonic-clonic	O	S_disease
convulsions	convulsions	O	S_disease
since	since	O	O
he	he	O	O
was	was	O	O
56	56	O	O
years	years	O	O
old	old	O	O
.	.	O	O

After	after	O	O
substituting	substituting	O	O
VPA	vpa	O	O
with	with	O	O
zonisamide	zonisamide	O	O
,	,	O	O
the	the	O	O
serum	serum	O	O
sodium	sodium	S_chemicals	O
level	level	O	O
returned	returned	O	O
to	to	O	O
normal	normal	O	O
.	.	O	O

We	we	O	O
consider	consider	O	O
this	this	O	O
episode	episode	O	O
of	of	O	O
SIADH	siadh	O	S_disease
to	to	O	O
be	be	O	O
the	the	O	O
result	result	O	O
of	of	O	O
a	a	O	O
combination	combination	O	O
of	of	O	O
factors	factors	O	O
including	including	O	O
a	a	O	O
weakness	weakness	O	O
of	of	O	O
the	the	O	O
central	central	O	B_disease
nervous	nervous	O	B_disease
system	system	O	I_disease
and	and	O	O
the	the	O	O
long-term	long-term	O	O
administration	administration	O	O
of	of	O	O
VPA	vpa	O	O
.	.	O	O

